CA-VELODYNE-LIDAR,-INC.
7.1.2020 03:02:12 CET | Business Wire | Press release
Velodyne Lidar, Inc. today announced Anand Gopalan as its new CEO. Gopalan, who previously was Velodyne’s CTO, assumes the position from Velodyne’s legendary founder David Hall. Hall will continue as full-time Chairman of the Board and remain actively involved in directing the company’s technology, product vision and business strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200106006044/en/
Gopalan is a distinguished engineer and technology executive with experience building and leading worldwide engineering organizations. He came to Velodyne in 2016 to form an advanced research and development team. Gopalan leads Velodyne’s customer-focused technology and product development teams to address market needs for lidar solutions designed for high performance, cost optimization and high-volume production.
Over the past three years, Gopalan has worked closely with Hall to develop the company’s technological roadmap and strategic vision. Gopalan is recognized across the industry as a thought leader in business as well as in technology. Recently, Gopalan became more active as a spokesman for the company, expertly explaining the benefits and the workings of lidar to audiences around the world. It is the policy of Velodyne to promote from within the company and Gopalan was a natural choice, having proved himself in 2019.
Gopalan and the Velodyne team look forward to building on the company’s growth trajectory. Due to the breadth and versatility of the Velodyne lidar portfolio, the company continues to make revolutionary contributions to the ever-expanding autonomous industry. Velodyne is a recognized leader in a wide range of markets including automotive, mapping, on-demand mobility, robotics, security, unmanned aerial vehicles (UAV) and more.
Under Gopalan’s leadership alongside Hall, Velodyne brought to market a series of breakthrough lidar products, including the Alpha Prime™, Velarray™, VelaDome™ and a new game-changing lidar sensor, soon to be used for powerful Advanced Driver Assistance Systems (ADAS). Due to its low cost, this sensor will advance automotive safety for the everyday car owner. At CES 2020, Velodyne will unveil the new lidar sensor and Gopalan will discuss his vision for the company at a press conference in the Velodyne booth #7520 on Tuesday, January 7, at 11:00 a.m. PST.
David Hall invented groundbreaking 3D lidar sensor technology in 2005 which set the stage for revolutionizing the automobile industry and was the foundation for Velodyne’s market leadership. The idea of leveraging lidar technology for autonomous driving came to Hall while participating in the DARPA Grand Challenge for autonomous vehicles. Holding more than 30 U.S. patents, Hall is a technology visionary and serial inventor covering a variety of applications, including lidar, audio and marine. The Intellectual Property Owners Education Foundation presented Hall with its 2018 Inventor of the Year Award.
“Anand Gopalan and I have worked side-by-side on Velodyne’s technology roadmap. He is the right executive to lead Velodyne in its next growth phase,” said Hall. “His finger is on the pulse of customer and market needs while possessing the technical brilliance and leadership skills to innovate and deliver. As Chairman, Anand has my full support while I continue to provide vision, strategize and invent.”
“David Hall is more than the founder of Velodyne, he is also the founder of our industry. I am grateful for the trust he has placed in me and excited to lead a company with such a deep history in innovation as Velodyne. We are the forefront of our market, ready to drive the age of autonomy. Velodyne is bringing improved mobility and safety through versatility, responsiveness and agility,” said Gopalan.
Elevating Gopalan to CEO will enhance the leadership team at Velodyne Lidar, running day-to-day business as the company addresses U.S. and global market opportunities. Gopalan and Hall will continue to be supported by a strong bench of Velodyne executive C-staff, including Marta Hall, Chief Marketing Officer (CMO), Rick Tewell, Chief Operating Officer (COO), Mike Jellen, Chief Commercial Officer (CCO), Drew Hamer, Chief Financial Officer (CFO), Barbara Rogan, General Counsel, and Mircea Gradu, Senior Vice President of Product and Quality.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s Founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™ and the groundbreaking software for driver assistance, Vella™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106006044/en/
Contact:
Sean Dowdall Landis Communications Inc. for Velodyne Lidar, Inc. (415) 286-7121 velodyne@landispr.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom